Literature DB >> 23596064

Peripheral blood HIV DNA is associated with atrophy of cerebellar and subcortical gray matter.

Kalpana J Kallianpur1, Cecilia Shikuma, Gregory R Kirk, Bruce Shiramizu, Victor Valcour, Dominic Chow, Scott Souza, Beau Nakamoto, Napapon Sailasuta.   

Abstract

OBJECTIVE: We evaluated regional brain volumes and cerebral metabolite levels as correlates of HIV DNA in peripheral blood mononuclear cells (PBMCs).
METHODS: In this cross-sectional study, 35 HIV+ subjects aged ≥40 years (25 with detectable PBMC HIV DNA; 10 with HIV DNA <10 copies/10(6) cells, the threshold of detection) and 12 seronegative controls underwent structural brain MRI and magnetic resonance spectroscopy at 3 T. HIV+ subjects were on combination antiretroviral therapy ≥1 year; all but 1 had plasma HIV RNA <50 copies/mL. We used logistic regression to evaluate relationships of likely predictor variables to the outcome of PBMC HIV DNA detectability in the HIV+ subjects. Effects of serostatus and HIV DNA on regional brain volumes (normalized to intracranial volume) and on metabolite ratios over creatine were evaluated by analyses of covariance, controlling for age.
RESULTS: Relative to the HIV+ group with undetectable HIV DNA, subjects with detectable HIV DNA demonstrated decreased volumes of cerebellar (-14%, p = 0.020) and total subcortical (-10%, p = 0.024) gray matter. Compared to healthy controls, only the detectable HIV DNA group showed significant (p < 0.05) enlargement of lateral ventricles and volumetric reductions of caudate, putamen, thalamus, hippocampus, nucleus accumbens, brainstem, total cortical gray matter, and cerebral white matter. Detectable HIV DNA was not associated with significantly altered cerebral metabolite levels.
CONCLUSION: Inability to clear peripheral blood of HIV DNA is associated with regional brain atrophy in well-controlled HIV infection, supporting the involvement of peripheral viral reservoirs in the neuropathogenesis of persistent HIV-related neurocognitive disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596064      PMCID: PMC3719430          DOI: 10.1212/WNL.0b013e318291903f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Feline immunodeficiency virus causes increased glutamate levels and neuronal loss in brain.

Authors:  C Power; T Moench; J Peeling; P A Kong; T Langelier
Journal:  Neuroscience       Date:  1997-04       Impact factor: 3.590

2.  Automatically parcellating the human cerebral cortex.

Authors:  Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Cereb Cortex       Date:  2004-01       Impact factor: 5.357

3.  Enlarged Virchow-Robin spaces: do they matter?

Authors:  F Barkhof
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

4.  Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages.

Authors:  Z G Jiang; C Piggee; M P Heyes; C Murphy; B Quearry; M Bauer; J Zheng; H E Gendelman; S P Markey
Journal:  J Neuroimmunol       Date:  2001-07-02       Impact factor: 3.478

5.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

6.  HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998.

Authors:  N Sacktor; R H Lyles; R Skolasky; C Kleeberger; O A Selnes; E N Miller; J T Becker; B Cohen; J C McArthur
Journal:  Neurology       Date:  2001-01-23       Impact factor: 9.910

7.  Increased glutamate in CSF and plasma of patients with HIV dementia.

Authors:  C Ferrarese; A Aliprandi; L Tremolizzo; L Stanzani; A De Micheli; A Dolara; L Frattola
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

8.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume.

Authors:  Randy L Buckner; Denise Head; Jamie Parker; Anthony F Fotenos; Daniel Marcus; John C Morris; Abraham Z Snyder
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

9.  Mild brain atrophy in early HIV infection: the lack of association with cognitive deficits and HIV-specific intrathecal immune response.

Authors:  I Elovaara; E Poutiainen; R Raininko; L Valanne; A Virta; S L Valle; J Lähdevirta; M Iivanainen
Journal:  J Neurol Sci       Date:  1990-11       Impact factor: 3.181

10.  Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss.

Authors:  Sarah L Archibald; Eliezer Masliah; Christine Fennema-Notestine; Thomas D Marcotte; Ronald J Ellis; J Allen McCutchan; Robert K Heaton; Igor Grant; Margaret Mallory; Aida Miller; Terry L Jernigan
Journal:  Arch Neurol       Date:  2004-03
View more
  48 in total

Review 1.  Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer's Disease: an Emerging Issue in Geriatric NeuroHIV.

Authors:  Benedetta Milanini; Victor Valcour
Journal:  Curr HIV/AIDS Rep       Date:  2017-08       Impact factor: 5.071

2.  Lower total and regional grey matter brain volumes in youth with perinatally-acquired HIV infection: Associations with HIV disease severity, substance use, and cognition.

Authors:  C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang
Journal:  Brain Behav Immun       Date:  2017-01-10       Impact factor: 7.217

Review 3.  Novel Neuroimaging Methods to Understand How HIV Affects the Brain.

Authors:  Paul M Thompson; Neda Jahanshad
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

4.  Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice.

Authors:  Aditya N Bade; Santhi Gorantla; Prasanta K Dash; Edward Makarov; Balasrinivasa R Sajja; Larisa Y Poluektova; Jiangtao Luo; Howard E Gendelman; Michael D Boska; Yutong Liu
Journal:  Mol Neurobiol       Date:  2015-06-11       Impact factor: 5.590

5.  Logistic Regression Confined by Cardinality-Constrained Sample and Feature Selection.

Authors:  Ehsan Adeli; Xiaorui Li; Dongjin Kwon; Yong Zhang; Kilian M Pohl
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  2019-02-26       Impact factor: 6.226

Review 6.  Treating HIV Infection in the Central Nervous System.

Authors:  A Calcagno; G Di Perri; S Bonora
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

7.  Association of Brain Structure Changes and Cognitive Function With Combination Antiretroviral Therapy in HIV-Positive Individuals.

Authors:  Ryan Sanford; Lesley K Fellows; Beau M Ances; D Louis Collins
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

Review 8.  Neuroimaging of HIV-associated neurocognitive disorders (HAND).

Authors:  Beau M Ances; Dima A Hammoud
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

9.  Accelerated and Premature Aging Characterizing Regional Cortical Volume Loss in Human Immunodeficiency Virus Infection: Contributions From Alcohol, Substance Use, and Hepatitis C Coinfection.

Authors:  Adolf Pfefferbaum; Natalie M Zahr; Stephanie A Sassoon; Dongjin Kwon; Kilian M Pohl; Edith V Sullivan
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-07-04

10.  Chained regularization for identifying brain patterns specific to HIV infection.

Authors:  Ehsan Adeli; Dongjin Kwon; Qingyu Zhao; Adolf Pfefferbaum; Natalie M Zahr; Edith V Sullivan; Kilian M Pohl
Journal:  Neuroimage       Date:  2018-08-21       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.